Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Arvind Ravi MD, PhD

Arvind Ravi MD, PhD

Medical Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts

Dr. Arvind Ravi is a medical oncologist at Dana-Farber Cancer Institute in Boston. He completed his medical training in the joint Harvard-MIT HST program, during which he obtained a PhD in Biology from MIT. After graduation, he completed residency training in internal medicine at Brigham and Women’s Hospital, followed by a medical oncology fellowship in the combined Dana-Farber/Massachusetts General Hospital training program.

He is a recipient of a 2019 ASCO Foundation Conquer Cancer Young Investigator Award as well as an NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers. His current research aims to understand the molecular underpinnings of intrinsic and acquired resistance in advanced cancers.

He is a member of the American Society of Clinical Oncology and the American Association of Cancer Research among other organizations.

Disclosures

Dr. Ravi reports the following: advisory/consulting: Tyra, Halo, AccessHope.

 

Recent Contributions to PracticeUpdate:

  1. Cell Death–Induced Immunogenicity Enhances Chemoimmunotherapeutic Response by Converting Immune-Excluded Into T-cell Inflamed Bladder Tumors
  2. RAF1 Amplification Drives a Subset of Bladder Tumors and Confers Sensitivity to MAPK-Directed Therapeutics

Recently Updated